Immunome Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Immunome Inc. (IMNM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IMNM insiders buying or selling?
In the last 12 months, Immunome Inc. insiders reported 7 open-market purchases ($2.1M) and 14 sales ($27.3M) — net selling of $25.2M. Since October 2020, Trabud has recorded 45 Form 4 filings for IMNM: 29 buys ($12.6M) and 16 sells ($27.6M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $1000.0K by Clay B Siegall (President and CEO) on Dec 18, 2025. SEC ↗
- The most recent open-market purchase was reported on May 19, 2026 (5 months ago).
Key Statistics (October 2020 – Sep 15, 2026)
Total Form 4 filings
45
SEC EDGAR
Insider filers
14
Insider buys (29)
$12.6M
Insider sells (16)
$27.6M
Insider sentiment
Net sellingNet insider flow of $15.0M in net selling since October 2020, and $25.2M in net selling over the last 12 months.
Recent IMNM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Jack Higgins | Chief Scientific Officer | Sale | 13.2K | $25.32 | $334.2K | SEC ↗ |
| Aug 12, 2026 | Isaac Barchas | Director | Sale | 83.5K | $26.35 | $2.2M | SEC ↗ |
| Aug 10, 2026 | Isaac Barchas | Director | Sale | 36.1K | $26.06 | $940.5K | SEC ↗ |
| Aug 6, 2026 | Kinney Horn | CHIEF BUSINESS OFFICER | Sale | 90.6K | $25.09 | $2.3M | SEC ↗ |
| Jul 9, 2026 | Kinney Horn | CHIEF BUSINESS OFFICER | Sale | 1.1K | $25.00 | $27.3K | SEC ↗ |
| Jul 7, 2026 | Isaac Barchas | Director | Sale | 100.0K | $24.13 | $2.4M | SEC ↗ |
| Jul 7, 2026 | Robert Lechleider | Chief Medical Officer | Sale | 55.0K | $22.62 | $1.2M | SEC ↗ |
| Jul 3, 2026 | Isaac Barchas | Director | Sale | 201.1K | $21.85 | $4.4M | SEC ↗ |
| Jun 29, 2026 | Robert Lechleider | Chief Medical Officer | Sale | 55.0K | $19.85 | $1.1M | SEC ↗ |
| Jun 17, 2026 | Max Rosett | Chief Financial Officer | Sale | 60.0K | $18.23 | $1.1M | SEC ↗ |
| May 19, 2026 | Jean Jacques Bienaime | Director | Purchase | 5.0K | $20.70 | $103.5K | SEC ↗ |
| Apr 3, 2026 | Jack Higgins | Chief Scientific Officer | Sale | 9.4K | $21.64 | $204.2K | SEC ↗ |
| Apr 3, 2026 | Max Rosett | Chief Financial Officer | Sale | 65.0K | $21.92 | $1.4M | SEC ↗ |
| Mar 31, 2026 | Clay B Siegall | President and CEO | Purchase | 25.4K | $19.67 | $500.6K | SEC ↗ |
| Mar 24, 2026 | WAGENHEIM PHILIP | Director | Sale | 65.0K | $20.55 | $1.3M | SEC ↗ |
| Mar 12, 2026 | Jean Jacques Bienaime | Director | Purchase | 2.0K | $21.84 | $43.7K | SEC ↗ |
| Dec 30, 2025 | Clay B Siegall | President and CEO | Purchase | 4.7K | $21.15 | $100.0K | SEC ↗ |
| Dec 23, 2025 | Isaac Barchas | Director | Sale | 383.2K | $21.74 | $8.3M | SEC ↗ |
| Dec 22, 2025 | Clay B Siegall | President and CEO | Purchase | 7.3K | $20.48 | $149.1K | SEC ↗ |
| Dec 22, 2025 | Philip Tsai | Chief Technical Officer | Purchase | 10.0K | $20.49 | $204.9K | SEC ↗ |
| Dec 18, 2025 | Clay B Siegall | President and CEO | Purchase | 46.5K | $21.50 | $1000.0K | SEC ↗ |
| Jun 4, 2025 | Jean Jacques Bienaime | Director | Purchase | 5.0K | $9.38 | $46.9K | SEC ↗ |
| Mar 26, 2025 | Jean Jacques Bienaime | Director | Purchase | 7.8K | $7.78 | $60.7K | SEC ↗ |
| Mar 26, 2025 | Clay B Siegall | President and CEO | Purchase | 137.1K | $7.29 | $999.5K | SEC ↗ |
| Mar 25, 2025 | Jean Jacques Bienaime | Director | Purchase | 7.0K | $8.21 | $57.5K | SEC ↗ |
Showing the 25 most recent of 45 Form 4 filings for Immunome Inc..
Most active IMNM insiders
- Clay B Siegall9 filings
- Jean Jacques Bienaime7 filings
- Isaac Barchas5 filings
- RAPP MICHAEL4 filings
- Jack Higgins3 filings
Ask anything about IMNM insider activity
Use Trabud's AI agent to query Immunome Inc.'s Form 4 history in plain English — "Show me IMNM CEO purchases this year" or compare it against any other ticker.
Open the AI agentIMNM insider trading FAQ
Are Immunome Inc. insiders buying or selling?
In the last 12 months, Immunome Inc. insiders reported 7 open-market purchases ($2.1M) and 14 sales ($27.3M) — net selling of $25.2M. Since October 2020, Trabud has recorded 45 Form 4 filings for IMNM: 29 buys ($12.6M) and 16 sells ($27.6M). Over the full record that is net selling of $15.0M.
How many insiders trade IMNM stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Immunome Inc.. The most recent filing was accepted on Sep 15, 2026.
Where does Trabud get IMNM insider trading data?
All IMNM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.